1.74
-0.065(-3.61%)
Currency In USD
| Previous Close | 1.8 |
| Open | 1.79 |
| Day High | 1.84 |
| Day Low | 1.73 |
| 52-Week High | 9.69 |
| 52-Week Low | 1.71 |
| Volume | 114,834 |
| Average Volume | 416,001 |
| Market Cap | 92.6M |
| PE | -1.52 |
| EPS | -1.14 |
| Moving Average 50 Days | 2.37 |
| Moving Average 200 Days | 4.91 |
| Change | -0.07 |
If you invested $1000 in TScan Therapeutics, Inc. (TCRX) since IPO date, it would be worth $171.43 as of March 13, 2025 at a share price of $1.8. Whereas If you bought $1000 worth of TScan Therapeutics, Inc. (TCRX) shares 3 years ago, it would be worth $494.51 as of March 13, 2025 at a share price of $1.8.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
TScan Therapeutics Announces Upcoming Presentation at the TD Cowen 45th Annual Health Care Conference
GlobeNewswire Inc.
Feb 27, 2025 12:00 PM GMT
WALTHAM, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients
TScan Therapeutics to Participate in the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference
GlobeNewswire Inc.
Feb 18, 2025 12:00 PM GMT
WALTHAM, Mass., Feb. 18, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients
TScan Therapeutics Announces $30 Million Registered Direct Offering at a 37% Premium
GlobeNewswire Inc.
Dec 26, 2024 12:00 PM GMT
WALTHAM, Mass., Dec. 26, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients